Grants for Special District Governments

"Fluctuating cognition can occur in many types of dementia and is a core clinical feature of Dementia with Lewy Bodies. Cognitive fluctuations can last from seconds to days, are unpredictable (e.g., do not just occur in the evenings, as with sun-downing), and are associated with poor daily functioning for the patient. A number of small studies have suggested that cognitive fluctuations in subjects with dementia may be related to epileptiform discharges and impaired oscillatory activity on EEG, but it is not clear that these are the only factors involved in patient populations that often experience dysautonomia, orthostasis, and sleep disturbances. The etiology of cognitive fluctuations may be multi-factorial and may vary in different dementia populations. Understanding the physiology related to cognitive fluctuations is a critical next step to the development of treatment approaches and improving quality of life for these patients. This initiate would encourage research that will better characterize the physiology responsible for cognitive fluctuations in ADRD populations. Given their variable appearance and time course, it is anticipated that wearable digital devices will be important for capturing fluctuations in a timely fashion, and applicants should consider incorporating those device(s) capable of acquiring the relevant data to support the hypothesized mechanism(s). Applicants may focus on assessing multiple mechanisms in a specific ADRD population, or may chose to compare mechanisms across multiple types of ADRDs. "

With this solicitation, BJA seeks to provide grants to jurisdictions to improve outcomes for adults on community supervision. The Second Chance Act (SCA) of 2007 (Public Law 110-199), reauthorized by the First Step Act of 2018, provides a comprehensive response to assist in the transition individuals make from adult confinement facilities (e.g., jails, prisons, detention centers) to their communities so that the transition is successful and promotes public safety. The SCA is designed to help communities develop and implement comprehensive strategies that address the challenges posed by reentry and recidivism reduction. The Smart Supervision Program is part of the SCA suite of programs in fiscal year (FY) 2024.

This program provides financial assistance to local governments in Colorado to address the community impacts of limited stakes gaming by funding public facilities and services.

The Emergency Solutions Grant Program (ESG), initially established as the Emergency Shelter Grant Program in 1987 under the Stewart B. McKinney Homeless Assistance Act, underwent significant revisions with the Homeless Emergency Assistance and Rapid Transition to Housing (HEARTH) Act of 2009. The program, aimed at addressing homelessness, is funded by the U.S. Department of Housing and Urban Development and administered by the Alabama Department of Economic and Community Affairs. ESG supports the upgrade of homeless and domestic abuse shelters, covers operating costs, provides essential services to homeless individuals, aids in homelessness prevention, facilitates rapid re-housing, and supports the Homeless Management Information System's administrative costs. Grant renewed every year.

This program provides funding to Arkansas communities for projects that improve transportation options and safety for pedestrians and cyclists.

This funding opportunity provides financial support to state agencies, nonprofit organizations, local governments, and tribal governments to improve law enforcement strategies and victim services aimed at reducing violence against women.

This program provides funding to public entities and nonprofit organizations in Arkansas for the construction and maintenance of recreational trails that are accessible to the general public.

The purpose of this NOFO is to solicit applications for Guardrail Safety Training program that will result in the award of one (1) cooperative agreement award and the distribution of up to $500,000.00 in Federal funding over the life of the project. The actual amount available to be awarded under this notice will be subject to the availability of funds. PROGRAM GOALS The goal of Guardrail Safety Training is three-fold:1. To provide technical assistance;2. To develop support materials for training activities; and3. To develop and conduct webinar trainings for roadway agency standards engineers/sections.Through the development of the products outlined in this cooperative agreement the desired outcome is improved guardrail design and installation.ADMINISTRATION GOALSThe FHWA seeks to fund tasks under this NOFO that advance the United States Department of Transportations National Roadway Safety Strategy (NRSS). The NRSS outlines the Departments comprehensive approach to significantly reducing serious injuries and deaths on our Nations highways, roads, and streets. This is the first step in working toward an ambitious long-term goal of reaching zero roadway fatalities.

The WORC Initiative aims to fund grants that create economic mobility, address inequities for historically marginalized communities of color, rural areas, and other underserved and underrepresented communities. These grants are designed to produce high-quality employment outcomes for workers in the Appalachian, Delta, and Northern Border regions, enabling them to remain and thrive in their communities. The Initiative provides grant funds to help impacted communities develop local and regional workforce development solutions aligned with existing economic development strategies and community partnerships, promoting new, sustainable job opportunities and long-term economic vitality with a focus on equity and underserved populations. WORC Round 6 places a strong emphasis on three key focus areas: enhancing access to Good Jobs, prioritizing equity, and sustaining impact. Questions regarding this Funding Opportunity Announcement (FOA) Forecast may be emailed to DOL-ETA-DWG@dol.gov; however, please note there is limited information that may be shared with the public, as this FOA is currently under development. We encourage prospective applicants and interested parties to use the Grants.gov subscription option to register for future updates provided for this particular FOA.

The purpose of this Notice of Funding Opportunity (NOFO) is to support collaborative, transdisciplinary, translational research projects which advance exceptionally promising, chemically complex botanical and other natural products relevant to dietary supplements towards highly informative clinical trials of their effects on quantitative, objective measures of human resilience. Dynamic, synergistic interactions among the range of experts required to ensure rigor in all aspects of this research will be supported by a multi-PD/PI team collaborating on a single set of integrated specific aims, culminating in data on optimal parameters for a future proposed clinical efficacy trial, as well as the development and validation of other critical knowledge and methods for interpretation of such a trial, such as clinical assessment of the engagement of an outcome-relevant target. Enhancing workforce and institutional capacity to conduct future rigorous, transdisciplinary research on chemically complex natural products must be built into the plans for research and for enhancing diverse perspectives. Achievement of the RM1 specific aims is expected to provide a strong foundation for a future highly informative clinical efficacy trial of the effects on resilience of a chemically complex natural product.This NOFO is one component of the Consortium Advancing Research on Botanicals and Other Natural Products (CARBON) Program. Other components of this Program include RFA-AT-24-008, Leveraging Data at Scale to Understand Natural Product Impacts on Whole Person Health (R01) and RFA-AT-24-007, Limited Competition: Research Resource for Natural Product Nuclear Magnetic Resonance Data (R24).

This grant provides funding for researchers to explore the complex interactions between the brain and immune system in the context of HIV and substance use disorders, aiming to identify new therapeutic targets and improve understanding of related neurological issues.

The National Center for Complementary and Integrative Health (NCCIH) with the Office of Dietary Supplements (ODS) solicit limited applications for continuation of an established nuclear magnetic resonance (NMR) research resource consisting of raw and meta-data from natural products ranging from crude extracts to purified substances; with the capacity to upload, download, store, search and analyze raw NMR data. The purpose of this limited competition is to promote sustainability, scaling and wider community inclusiveness of the established NMR research resource. This notice of funding opportunity (NOFO) is part of the Consortium Advancing Research on Botanicals and Other Natural Products (CARBON) Program. Other components of this Program include the Botanical Dietary Supplements Translational Research Teams (RM1) and Leveraging Big Data to Understand Natural Product Impacts on Whole Person Health (R01).

This grant provides funding for researchers to explore the interactions between the brain and immune system in the context of HIV and substance use disorders, aiming to identify new therapeutic targets and improve understanding of related neurological issues.

Notice of Funding Opportunity Description Background The Food and Drug Administration (FDA) protects the public health by ensuring that medical products intended to be marketed in the United States are safe and effective for their intended use. FDA stakeholders are exploring innovative ways to produce scientific evidence in support of regulatory submissions, including the development of new data sources, study designs, methodologies, and technologies. FDA encourages and facilitates the use of such innovative approaches while ensuring that the scientific evidence supporting marketing approvals meet our high evidentiary standards. The Prescription Drug User Fee Act VII (PDUFA VII) commitment letter represents the product of discussions between the FDA, regulated industry, and public stakeholders, as mandated by Congress. The performance and procedural goals and other commitments specified in the PDUFA VII commitment letter apply to aspects of the human drug review program that are important for facilitating timely access to safe, effective, and innovative new medicines for patients. The commitment letter includes goals relating to the use of digital health technologies (DHTs) to support drug development and review. A DHT is a system that uses computing platforms, connectivity, software, and/or sensors, for health care and related uses. DHTs for remote data acquisition in clinical investigations can include hardware and/or software to perform one or more functions. DHTs may rely on or work with other technologies that support their operation, such as general-purpose computing platforms (e.g., smartphones) and communication networks. Among other activities relating to the use of DHTs, FDA has established a Framework for the Use of DHTs in Drug and Biological Product Development to guide the use of DHT-derived data in regulatory decision-making for drugs (hereinafter Framework ). The Framework highlights FDA’s DHT efforts including workshops and demonstration projects; engagement with stakeholders; establishment of internal processes to support the evaluation of DHTs for use in drug development; promotion of shared learning and consistency regarding DHT-based policy, procedure, and analytic tool development; and publication of guidance documents. In addition, FDA’s webpage DHTs for Drug Development (available at: https://www.fda.gov/science-research/science-and-research-special-topics/digital-health-technologies-dhts-drug-development) provides an overview of the ongoing DHT efforts, including demonstration projects. A variety of project types are welcomed under this NOFO, applicable to drugs and biologics (not devices). FDA is particularly interested in projects that evaluate the use of DHTs in drug development. Project Objectives The overarching goal of this notice of funding opportunity (NOFO) is to explore the role of DHTs (e.g., actigraphy, photography, environmental sensors) in the evaluation of new drugs. These projects may involve engagement with researchers from academia, the biopharmaceutical industry, patient groups, and other stakeholders. The objectives of these projects are to advance DHTs for clinical drug development, expand the ability to capture early manifestations of chronic diseases, determine outcomes in populations with unmet medical needs and enhance convenience for trial participants by allowing for remote data acquisition in clinical investigations. The scope includes, but is not limited to, projects that focus on: Comparing digital measurements to traditional measurements in clinical trials to evaluate drugs Developing and evaluating novel endpoints using DHTs to address unmet needs for drug clinical trials (e.g., use of environmental sensors to capture apnea in pediatric patients) Comparing metrics to evaluate continuous measurements (e.g., maximum activity and stamina) Capturing early manifestations of chronic diseases (e.g., dementia) through the use of DHTs

Note: Each funding opportunity description is a synopsis of information in the Federal Register application notice. For specific information about eligibility, please see the official application notice. The official version of this document is the document published in the Federal Register. Free Internet access to the official edition of the Federal Register and the Code of Federal Regulations is available on GPO Access at: http://www.access.gpo.gov/nara/index.html. Please review the official application notice for pre-application and application requirements, application submission information, performance measures, priorities and program contact information. For the addresses for obtaining and submitting an application, please refer to our Revised Common Instructions for Applicants to Department of Education Discretionary Grant Programs, published in the Federal Register on December 7, 2022. Purpose of Program: The Braille Training program offers financial assistance to projects that will (1) provide training in the use of braille for personnel providing vocational rehabilitation (VR) services or educational services to youth and adults who are blind; (2) develop braille training materials; (3) develop methods used to teach braille; and (4) develop activities used to promote the knowledge and use of braille and nonvisual access technology for youth and adults who are blind. Assistance Listing Number (ALN) 84.235E.

This program provides funding to small local governments in Pennsylvania for community revitalization projects that benefit low- and moderate-income residents.

Notice of Funding Opportunity Description Background The accumulation of misprocessed and aberrant proteins is a defining characteristic of various neurodegenerative conditions, such as AD and frontotemporal lobar degeneration (FTLD). These atypical proteins may arise from various factors, such as somatic mutations, environmental changes, genomic instability, irregular RNA processing, and proteolytic cleavages, as well as incorrect folding and post-translational modifications. For instance, many recent proteome and transcriptome profiling of AD brains reveals RNA splicing dysfunction and abnormal accumulation of U1 small nuclear ribonucleoprotein (snRNP) and transactive response DNA-binding protein 43 (TDP-43). In AD, U1-70K and its N-terminal 40-KDa fragment (N40K) is one of the most abundant proteins in the insoluble fraction of cell lysates. TDP-43 is an RNA-binding protein. In AD, TDP-43 pathology is observed in approximately 25-50% of cases, particularly in cases with co-morbidities such as Lewy body dementia or hippocampal sclerosis. However, the relationship between U1snRNP/TDP-43 and AD pathology is complex and not fully understood. The disruption of RNA processing is thought to be one possible mechanism to cause the accumulation of misprocessed proteins, which can lead to altered expression of genes involved in AD pathology, including amyloid precursor protein (APP), tau, and synaptic proteins. Understanding the mechanisms underlying the dysregulation of misprocessed proteins in neurodegenerative diseases will be important for developing effective therapies. Approaches that target the production or aggregation of misprocessed proteins, or that promote their clearance or degradation, may be effective in preventing or slowing disease progression. Purpose This NOFO invites innovative research proposals to explore the accumulation of misprocessed proteins in Tauopathies within specific brain regions and cell types. This NOFO encourages collaborative efforts to create advanced single-cell or single-cell type proteogenomic platforms. These platforms aim to shed light on dynamic changes in protein-misfolding responses in neuronal proteomes and their potential biological consequences during aging and the development of AD/ADRD. Research Objectives This NOFO aims to provide a proof-of-principal for a novel strategy to identify misprocessed and aberrant proteins in Tau diseases using the proteogenomic approach. Proteogenomics is an integrated approach that combines proteomics and genomics data. In proteogenomics, genomic and transcriptomic experiments are more closely integrated to identify potential protein coding and non-coding regions in the genome. These regions are then validated using mass spectrometry-based proteomics. Proteogenomics has emerged as a powerful tool for investigating the role of protein homeostasis in AD pathogenesis, especially in the context of mis-translated and mis-repaired proteins. However, relying solely on misprocessed protein levels to draw conclusions about biological processes is unlikely to be reliable. Therefore, an intermediate layer of functional validation is essential to transform proteogeomic data into meaningful biological information. As a result, the objective of this NOFO is not only to confirm changes in protein abundance using other methods, but also to assess the biological effects of those changes in some model systems, especially in the area of tauopathies, to ensure high interlaboratory reproducibility. Using the proteogenomics approach, this NOFO aims to accomplish the following: Create a comprehensive database of misprocessed and aberrant proteins in selected mouse models of human Tau diseases. Cross-validate the presence of misprocessed and aberrant proteins in human AD/ADRD brains. Identify new molecular pathways and novel misprocessed protein-protein interaction networks that are not currently in most datasets. Define novel mechanisms through which misprocessed and aberrant proteins influence the onset and progression of neurodegeneration in tauopathies. Identify disease specific therapeutic targets in neurodegenerative diseases. It is expected that applications responding to this initiative will use the latest cell-type-specific labeling and proteogenomic techniques with suitable model systems to understand the etiology of tauopathies in aging and AD.

The specific purpose of this NOFO is to promote the development of a diverse, interdisciplinary workforce needed to conduct translational research on Alzheimer's disease and Alzheimer's-related dementias from target discovery through clinical development. This NOFO will support institutional training programs for predoctoral and postdoctoral level researchers with diverse educational backgrounds (i.e., basic biology, translational and clinical research, data science). The program invites eligible institutions to develop interdisciplinary training programs that will provide trainees with the knowledge and skills in data science, disease biology, behavioral research, and traditional and emerging drug discovery disciplines necessary to conduct rigorous and cutting-edge basic, translational, and clinical research for AD/ADRD.

This funding opportunity provides financial support for research facilities to acquire modern equipment that measures environmental factors affecting animal research, enhancing the reliability and reproducibility of scientific studies.

This program provides funding to municipalities, nonprofits, educational institutions, and other organizations in Pennsylvania for the development and improvement of parks, trails, and recreational spaces to enhance community livability and promote conservation.